Tumor cells were negative for EMA, transthyretin, myogenin, desmin, progesterone receptor, NeuN, Olig-2, TTF-1, GATA3, PAX8, OCT3/4, SALL4, CD117, S100 and GFAP. Vasculature was highlighted by PAS, reticulin, CD31, ERG, and CD34. INI-1 was intact in the nuclei. Final diagnosis was...
Interestingly, the tumor contained a 3 mm focus of a lesion staining positive for Thyroid Transcrip- tion Factor-1 (TTF1), Thyroglobulin, and was negative for RCC marker (Fig. 2a, b). This finding led to the diag- nosis of a tumor-to-tumor metastasis of PTC to CCRCC. The gross ...
blood samples from enrolled patients. Upon immunofluorescence analysis, the enriched cells showed positive markers for EpCAM, TTF-1, synaptophysin and negative for CD45. Additionally, the expanded CTCs demonstrated marked heterogeneity in the expression of E-cadherin and N-cadherin. In a prelim...
2a). In addition, tumors in both groups were positive for surfactant protein C (SFTPC) but negative for Clara cell secretory protein (CCSP) (Fig. 2a), suggesting that the tumors arose from alveolar cells. These results showed that Med23 deficiency did not appear to affect cell origin or ...
bodies of granulosa cell tumor. The presence of other teratomatous components would render a diagnosis of struma ovarii much more probable. Immunostains are definitive in all these differentials because sex cord–stromal tumors are positive forinhibin,calretinin, and SF1 and negative for TTF-1. ...
0511U Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-hyphenresponse prediction for each drug [PARIS Test (chemosensitivity assay)] 0564T Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs ...
Interestingly, the tumor contained a 3 mm focus of a lesion staining positive for Thyroid Transcription Factor-1 (TTF1), Thyroglobulin, and was negative for RCC marker (Fig. 2a, b). This finding led to the diagnosis of a tumor-to-tumor metastasis of PTC to CCRCC. The gross specimen was...
CLDN18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors. With its specific expression pattern, CLDN18.2 has become a unique molecule for ...
2A). IHC demonstrated positivity of the tumor cells for anti-S100 (Fig. 2B) and antivimentin stains (Fig. 2C), but CK7, SMA, and TTF-1 immunostains were negative. Both morphological findings and immunophenotypes were compatible with malignant peripheral nerve sheath tumor with rhabdomyoblastic...
The tumor cells were immunpositive for cytokeratin (CK), CK7, epithelial membrane antigen, carcinoembryonic antigen and showed diffuse and strong nuclear positivity for thyroid transcription factor 1. They were negative for neuroendocrine markers and pituitary hormones. Ki-67 proliferation index was low ...